Information Provided By:
Fly News Breaks for July 17, 2017
BSX
Jul 17, 2017 | 08:00 EDT
Cowen analyst Joshua Jennings believes Boston Scientific can retain its position as one of the premier large cap Med-Tech growth stories and does not expect Q2 results to slow its momentum. He believes its top line growth performance will remain and said it is possible to see another positive guidance revision. Jennings reiterated his Outperform rating and $31 price target on Boston Scientific shares.
News For BSX From the Last 2 Days
BSX
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BSX
BSX
BSX
BSX
BSX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.